Autoantibody reactive with RNA polymerase III in systemic sclerosis

Area of Science:

• Rheumatology
• Immunology
• Autoimmunity

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis of the skin and internal organs.
• Autoantibodies play a crucial role in SSc pathogenesis and classification.
• The clinical significance of anti-RNA polymerase III antibody in SSc requires further elucidation.

Purpose of the Study:

• To investigate the prevalence and clinical significance of anti-RNA polymerase III antibody in patients with systemic sclerosis (SSc).
• To compare the clinical features of SSc patients with and without anti-RNA polymerase III antibody.

Main Methods:

• A point prevalence study involving 252 SSc patients and 170 controls.
• Autoantibody detection using immunoprecipitation, immunoblotting, and immunodepletion.
• Longitudinal examination of clinical significance.

Main Results:

• Anti-RNA polymerase III antibody was detected in 23% of SSc patients, significantly higher than in controls.
• The antibody was more prevalent in diffuse cutaneous SSc (dcSSc) (45%) than limited cutaneous SSc (6%).
• Patients with anti-RNA polymerase III antibody showed higher skin thickness but lower frequencies of telangiectasias, myopathy, lung, and cardiac disease compared to those with anti-topoisomerase I antibody.

Conclusions:

• Anti-RNA polymerase III antibody is a novel autoantibody marker for SSc, particularly for patients with diffuse or extensive cutaneous involvement.
• This antibody is associated with distinct clinical features in SSc.
• Further research is warranted to understand the full implications of anti-RNA polymerase III antibody in SSc.